Poxel S.A. (EPA:POXEL)

Market Cap	23.24M
Revenue (ttm)	2.19M
Net Income (ttm)	-16.11M
Shares Out	53.67M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,688,250
Average Volume	1,551,810
Open	0.4400
Previous Close	0.4600
Day's Range	0.3885 - 0.4990
52-Week Range	0.1150 - 0.8960
Beta	1.84
RSI	63.05
Earnings Date	Apr 22, 2025

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatoh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 6
• Stock Exchange: Euronext Paris
• Ticker Symbol: POXEL

Financial Performance

In 2023, Poxel's revenue was 1.98 million, an increase of 193.92% compared to the previous year's 674,000. Losses were -35.09 million, 11.8% more than in 2022.